Shire’s Cinryze has made some headway as a preventative therapy for hereditary angioedema (HAE) but its need for twice-weekly intravenous dosing leaves a lot to be desired – and plenty of patients on the sideline. CSL and Shire are hoping to change practice patterns with Haegarda and lanadelumab, which are approaching a PDUFA date and a Phase III readout, respectively.
To provide FirstWord readers with a better understanding of the competitive dynamic for preventative HAE therapies, we are hosting an expert call with a key opinion leader later this week.
Key topics that will be discussed during the call include, among other things… how impressive are the Phase III results for twice-weekly subcutaneous Haegarda; how much of an advantage is Haegarda’s dosing profile and to what percentage of new and existing patients might it be prescribed; feedback on Phase Ib data for twice-monthly subcutaneous lanadelumab; and thoughts on what sort of efficacy trade-off might be acceptable for the added convenience of lanadelumab?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment paradigm for HAE prophylaxis.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.